April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Rho Kinase Inhibitor AMA0526 Improves Surgical Outcome in a Rabbit Model of Glaucoma Filtration Surgery
Author Affiliations & Notes
  • Sarah Van de Velde
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Tine Van Bergen
    Lab of Ophthalmology, KULeuven, Leuven, Belgium
  • Evelien Vandewalle
    Ophthalmology, UZ Leuven, Leuven, Belgium
  • Karolien Castermans
    Amakem Ophthalmics, Diepenbeek, Belgium
  • Nele Kindt
    Amakem Ophthalmics, Diepenbeek, Belgium
  • Lieve K M Moons
    Department of Biology, KULeuven, Leuven, Belgium
  • Ingeborg Stalmans
    Ophthalmology, UZ Leuven, Leuven, Belgium
  • Footnotes
    Commercial Relationships Sarah Van de Velde, Amakem Ophthalmics (F); Tine Van Bergen, None; Evelien Vandewalle, None; Karolien Castermans, Amakem Ophthalmics (E); Nele Kindt, Amakem Ophthalmics (E); Lieve Moons, None; Ingeborg Stalmans, Amakem Ophthalmics (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3207. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Van de Velde, Tine Van Bergen, Evelien Vandewalle, Karolien Castermans, Nele Kindt, Lieve K M Moons, Ingeborg Stalmans; Rho Kinase Inhibitor AMA0526 Improves Surgical Outcome in a Rabbit Model of Glaucoma Filtration Surgery. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3207.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To elucidate the effect of a locally acting, selective ROCK inhibitor on the wound healing process and surgical outcome of glaucoma filtration surgery.

Methods: The in vitro effect of ROCK inhibitor AMA0526 (0.1-25µM) on human brain microvascular endothelial cells (HBMEC) and human Tenon fibroblasts (HTF) was determined using a proliferation assay. Secondly the in vivo effect of topical AMA0526 0.3% TID was investigated in a rabbit model of glaucoma filtration surgery (n=5/time point). Treatment outcome was studied by clinical investigation of the bleb area as well as immunohistological analyses for inflammation (CD45), angiogenesis (CD31) and collagen deposition (Sirius Red) at day 8, 14 and 30 after surgery. Contralateral eyes were used as control and were treated with vehicle.

Results: A dose-dependent reduction (0.1-25µM) of HBMEC and HTF proliferation was measured after incubation with AMA0526 (P<0.05). Incubation with the highest concentration of AMA0526 reduced proliferation of HBMEC and HTF to 22 and 35%. In the surgery model, AMA0526 significantly improved bleb area and survival compared to vehicle treated eyes (P<0.05). Immunohistological analyses showed significant reduction of inflammation, angiogenesis and collagen deposition after treatment with the ROCK inhibitor. Compared to vehicle, inflammation was decreased by 33% at 8 days (P<0.05), angiogenesis was reduced by 52% on day 8 and by 29% at 14 days (P<0.01), and collagen deposition by 30% on surgical day 30 (P<0.01).

Conclusions: This study shows that AMA0526 is able to inhibit proliferation of microvascular endothelial cells and Tenon fibroblasts in vitro, and to improve glaucoma surgery outcome in rabbits. In addition to improved bleb area, AMA0526 led to decreased inflammation, angiogenesis and fibrosis. This study can open new perspectives for a safer and more efficient glaucoma surgery.

Keywords: 765 wound healing  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×